

Supplemental References:

The following articles were referred to generate data and figures for this review:

GATA2 patients references: 1-29

RUNX1 patient references: 30-60

CEBPa patient references: 61-76

1. Ballerie A, Nimubona S, Meunier C, *et al.* Association of pulmonary alveolar proteinosis and fibrosis: patient with GATA2 deficiency. *Eur Respir J*, 2016. 48(5): p. 1510-1514.
2. Bődör C, Renneville A, Smith M, *et al.* Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival. *Haematologica*. 2012 Jun;97(6):890-4.
3. Bluteau O, Sebert M, Leblanc T, *et al.* A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. *Blood*, 2018. 113(7): p. 717-732.
4. Dickinson RE, Milne P, Jardine L, *et al.* The evolution of cellular deficiency in GATA2 mutation. *Blood*. 2014 Feb 6;123(6):863-74.
5. Donadieu J, Lamant M, Fieschi C, *et al.*, Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. *Haematologica*, 2018. 103(8): p. 1278-1287.
6. Drazer MW, Kadri S, Sukhanova M, *et al.* Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. *Blood Adv*, 2018. 2(2): p. 146-150.
7. Esparza O, Xavier AC, Atkinson TP, Hill BC, Whelan K. A unique phenotype of T-cell acute lymphoblastic leukemia in a patient with GATA2 haploinsufficiency. *Pediatr Blood Cancer*, 2019. 66(6): p. e27649.
8. Fujiwara T, Fukuhara N, Funayama R, *et al.*, Identification of acquired mutations by whole-genome sequencing in GATA-2 deficiency evolving into myelodysplasia and acute leukemia. *Ann Hematol*. 2014 Sep;93(9):1515-22.
9. Ganapathi KA, Townsley DM, Hsu AP *et al.* GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia. *Blood*, 2015. 125(1): p. 56-70.
10. Hahn CN, Chong CE, Carmichael CL *et al.* Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. *Nat Genet*. 2011 Sep 4;43(10):1012-7.
11. Holme H, Hossain U, Kirwan M *et al.* Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia. *Br J Haematol*. 2012 Jul;158(2):242-248.
12. Ishida H, Imai K, Honma K, *et al.* GATA-2 anomaly and clinical phenotype of a sporadic case of lymphedema, dendritic cell, monocyte, B- and NK-cell (DCML) deficiency, and myelodysplasia. *Eur J Pediatr*. 2012 Aug;171(8):1273-6.
13. Kazenwadel J, Secker GA, Liu YJ, *et al.* Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. *Blood*. 2012 Feb 2;119(5):1283-91.
14. Koegel AK, Hofmann I, Moffitt K, Degar B, Duncan C, Tubman VN. Acute lymphoblastic leukemia in a patient with MonoMAC syndrome/GATA2 haploinsufficiency. *Pediatr Blood Cancer*, 2016. 63(10): p. 1844-7.
15. McReynolds LJ, Yang Y, Yuen Wong H *et al.* MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations. *Leuk Res*, 2019. 76: p. 70-75.
16. Mendes-de-Almeida DP, Andrade FG, Borges G *et al.* GATA2 mutation in long stand *Mycobacterium kansasii* infection, myelodysplasia and MonoMAC syndrome: a case-report. *BMC Med Genet*, 2019. 20(1): p. 64.

17. Monif M, Huq A, Chee L, Kilpatrick T. MonoMac syndrome with associated neurological deficits and longitudinally extensive cord lesion. *BMJ Case Rep*, 2018. Apr 21;2018. pii: bcr-2017-222872.
18. Mutsaers PG, van de Loosdrecht AA, Tawana K, Bödör C, Fitzgibbon J, Menko FH. Highly variable clinical manifestations in a large family with a novel GATA2 mutation. *Leukemia*. 2013 Nov;27(11):2247-8.
19. Novakova M, Žaliová M, Suková M *et al.*, Loss of B cells and their precursors is the most constant feature of GATA-2 deficiency in childhood myelodysplastic syndrome. *Haematologica*, 2016. 101(6): p. 707-16.
20. Ostergaard P, Simpson MA, Connell FC *et al.* Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). *Nat Genet*. 2011 Sep 4;43(10):929-31.
21. Pasquet M, Bellanné-Chantelot C, Tavitian S *et al.* High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. *Blood*. 2013 Jan 31;121(5):822-9.
22. Polat A, Dinulescu M, Fraitag S *et al.* Skin manifestations among GATA2-deficient patients. *Br J Dermatol*, 2018. 178(3): p. 781-785.
23. Rastogi N, Abraham RS, Chadha R *et al.*, Successful Nonmyeloablative Allogeneic Stem Cell Transplant in a Child With Emberger Syndrome and GATA2 Mutation. *J Pediatr Hematol Oncol*, 2018. 40(6): p. e383-e388.
24. Shiba N, Funato M, Ohki K, *et al.*, Mutations of the GATA2 and CEBPA genes in paediatric acute myeloid leukaemia. *Br J Haematol*. 2014 Jan;164(1):142-5.
25. Sologuren I, Martínez-Saavedra MT, Solé-Violán J, *et al.* Lethal Influenza in Two Related Adults with Inherited GATA2 Deficiency. *J Clin Immunol*, 2018. 38(4): p. 513-526.
26. Weinberg OK, Kuo F, Calvo KR. Germline Predisposition to Hematolymphoid Neoplasia. *Am J Clin Pathol*. 2019 Aug 1;152(3):258-276.
27. West RR, Hsu AP, Holland SM, Cuellar-Rodriguez J, Hickstein DD. Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation. *Haematologica*, 2014. 99(2): p. 276-81.
28. Wlodarski MW, Hirabayashi S, Pastor V, *et al.*, Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. *Blood*, 2016. 127(11): p. 1387-97; quiz 1518.
29. Zhang MY, Keel SB, Walsh T *et al.* Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity. *Haematologica*, 2015. 100(1): p. 42-8.
30. Appelmann I, Linden T, Rudat A, *et al.* Hereditary thrombocytopenia and acute myeloid leukemia: a common link due to a germline mutation in the AML1 gene. *Ann Hematol*. 2009 Oct;88(10):1037-8.
31. Antony-Debre I, Duployez N, Bucci M *et al.* Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia. *Leukemia*, 2016. 30(4): p. 999-1002.
32. Buijs A1, Poddighe P, van Wijk R *et al.* A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. *Blood*. 2001 Nov 1;98(9):2856-8.
33. Buijs A, Poot M, van der Crabben S, *et al.* Elucidation of a novel pathogenomic mechanism using genome-wide long mate-pair sequencing of a congenital t(16;21) in a series of three RUNX1-mutated FPD/AML pedigrees. *Leukemia*. 2012 Sep;26(9):2151-4.
34. Cavalcante de Andrade Silva M, Krepischki ACV, Kulikowski LD *et al.* Deletion of RUNX1 exons 1 and 2 associated with familial platelet disorder with propensity to acute myeloid leukemia. *Cancer Genet*, 2018. 222-223: p. 32-37.

35. Chisholm KM, Denton C, Keel S, *et al.* Bone Marrow Morphology Associated With Germline RUNX1 Mutations in Patients With Familial Platelet Disorder With Associated Myeloid Malignancy. *Pediatr Dev Pathol*, 2019. 22(4): p. 315-328.
36. Churpek JE, Pyrtel K, Kanchi KL *et al.* Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. *Blood*, 2015. 126(22): p. 2484-90.
37. De Rocco D, Melazzini F, Marconi C *et al.* Mutations of RUNX1 in families with inherited thrombocytopenia. *Am J Hematol*, 2017. 92(6): p. E86-e88.
38. Haslam K, Langabeer SE, Hayat A, *et al.*, Targeted next-generation sequencing of familial platelet disorder with predisposition to acute myeloid leukaemia. *Br J Haematol*. 2016 Oct;175(1):161-3.
39. Joeïlle Michaud, Feng Wu, Motomi Osato, *et al.* In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. *Blood*. 2002 Feb 15;99(4):1364-72.
40. Jongmans MC, Kuiper RP, Carmichael CL *et al.* Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome. *Leukemia*. 2010 Jan;24(1):242-6.
41. Kanagal-Shamanna R, Loghavi S, DiNardo CD *et al.* Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. *Haematologica*, 2017. 102(10): p. 1661-1670.
42. Langabeer SE, Owen CJ, McCarron SL *et al.* A novel RUNX1 mutation in a kindred with familial platelet disorder with propensity to acute myeloid leukaemia: male predominance of affected individuals. *Eur J Haematol*. 2010 Dec;85(6):552-3.
43. Latger-Cannard V, , Philippe C, Bouquet A *et al.* Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders. *Orphanet J Rare Dis*, 2016. 11: p. 49.
44. Linden T, Schnittger S, Groll AH, *et al.* Childhood B-cell precursor acute lymphoblastic leukaemia in a patient with familial thrombocytopenia and RUNX1 mutation. *Br J Haematol*. 2010 Dec;151(5):528-30.
45. Manchev VT, Bouzid H, Antony-Debré I *et al.* Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0. *J Cell Mol Med*, 2017. 21(6): p. 1237-1242.
46. Marneth AE, van Heerde WL, Hebeda KM, *et al.* Platelet CD34 expression and alpha/delta-granule abnormalities in GFI1B- and RUNX1-related familial bleeding disorders. *Blood*, 2017. 129(12): p. 1733-1736.
47. Ng IK, Lee J, Ng C *et al.*, Preleukemic and second-hit mutational events in an acute myeloid leukemia patient with a novel germline RUNX1 mutation. *Biomark Res*, 2018. 6: p. 16.
48. Owen CJ, Toze CL, Koochin A, *et al.* Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. *Blood*. 2008 Dec 1;112(12):4639-45.
49. Perez Botero J, Chen D, Cousin MA, *et al.* Clinical characteristics and platelet phenotype in a family with RUNX1 mutated thrombocytopenia. *Leuk Lymphoma*, 2017. 58(8): p. 1963-1967.
50. Preudhomme C1, Renneville A, Bourdon V, *et al.* High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. *Blood*. 2009 May 28;113(22):5583-7.
51. Sakurai M, , Kasahara H, Yoshida K, *et al.* Genetic basis of myeloid transformation in familial platelet disorder/acute myeloid leukemia patients with haploinsufficient RUNX1 allele. *Blood Cancer J*, 2016. 6: p. e392.
52. Schmit JM, Turner DJ, Hromas RA, *et al.* Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome. *Leuk Res Rep*. 2015 Apr 3;4(1):24-7.

53. Shinawi M, Erez A, Shardy DL, *et al.* Syndromic thrombocytopenia and predisposition to acute myelogenous leukemia caused by constitutional microdeletions on chromosome 21q. *Blood*. 2008 Aug 15;112(4):1042-7.
54. Song WJ, Sullivan MG, Legare RD *et al.* Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. *Nat Genet*. 1999 Oct;23(2):166-75.
55. Stano Kozubik K, Radová L, Pešová M, *et al.* C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies. *Int J Hematol*, 2018. 108(6): p. 652-657.
56. Tawana K, Wang J, Király PA, *et al.* Recurrent somatic JAK-STAT pathway variants within a RUNX1-mutated pedigree. *Eur J Hum Genet*, 2017. 25(8): p. 1020-1024.
57. van der Crabben S, van Binsbergen E, Ausems M, *et al.* Constitutional RUNX1 deletion presenting as non-syndromic thrombocytopenia with myelodysplasia: 21q22 ITSN1 as a candidate gene in mental retardation. *Leuk Res*. 2010 Jan;34(1):e8-12.
58. Walker LC, Stevens J, Campbell H, *et al.* A novel inherited mutation of the transcription factor RUNX1 causes thrombocytopenia and may predispose to acute myeloid leukaemia. *Br J Haematol*. 2002 Jun;117(4):878-81.
59. Yoshimi A, Toya T, Kawazu M *et al.* Recurrent CDC25C mutations drive malignant transformation in FPD/AML. *Nat Commun*, 2014. 5: p. 4770.
60. Yoshimi A, Toya T, Nannya Y, *et al.* Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan. *Ann Oncol*, 2016. 27(5): p. 887-95.
61. Carmichael CL, Wilkins EJ, Bengtsson H, *et al.* Poor prognosis in familial acute myeloid leukaemia with combined biallelic CEBPA mutations and downstream events affecting the ATM, FLT3 and CDX2 genes. *Br J Haematol*, 2010. 150(3): p. 382-5.
62. Debeljak M, Kitanovski L, Pajič T, Jazbec J. Concordant acute myeloblastic leukemia in monozygotic twins with germline and shared somatic mutations in the gene for CCAAT-enhancer-binding protein alpha with 13 years difference at onset. *Haematologica*, 2013. 98(7): p. e73-4.
63. Gutman, J.A. and B. Hoffner, A novel CCAAT/enhancer binding protein alpha germline variant in a case of acute myeloid leukemia. *Leuk Lymphoma*, 2012. 53(5): p. 1006-7.
64. Kim HS, Han E, Jang W, *et al.* Germline CEBPA mutations in Korean patients with acute myeloid leukemia. *Leuk Res*, 2019. 76: p. 84-86.
65. Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. *J Clin Oncol*, 2008. 26(31): p. 5088-93.
66. Pathak A, Seipel K, Pemov A, *et al.* Whole exome sequencing reveals a C-terminal germline variant in CEBPA-associated acute myeloid leukemia: 45-year follow up of a large family. *Haematologica*, 2016. 101(7): p. 846-52.
67. Ram J, Flamm G, Balys M, *et al.* Index case of acute myeloid leukemia in a family harboring a novel CEBPA germ line mutation. *Blood Adv*, 2017. 1(8): p. 500-503.
68. Renneville A, Mialou V, Philippe N, *et al.* Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. *Leukemia*, 2009. 23(4): p. 804-6.
69. Sellick GS, Spendlove HE, Catovsky D, Pritchard-Jones K, Houlston RS. Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia. *Leukemia*, 2005. 19(7): p. 1276-8.
70. Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J. Mutation of CEBPA in familial acute myeloid leukemia. *N Engl J Med*, 2004. 351(23): p. 2403-7.
71. Stelljes M, Corbacioglu A, Schlenk RF, *et al.* Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein alpha from hematopoietic cells in a family with AML. *Leukemia*, 2011. 25(7): p. 1209-10.

72. Taskesen E, Bullinger L, Corbacioglu A, *et al.* Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. *Blood*, 2011. 117(8): p. 2469-75.
73. Tawana K, Wang J, Renneville A, *et al.*, Disease evolution and outcomes in familial AML with germline CEBPA mutations. *Blood*, 2015. 126(10): p. 1214-23.
74. Yan B, Ng C, Moshi G, *et al.* Myelodysplastic features in a patient with germline CEBPA-mutant acute myeloid leukaemia. *J Clin Pathol*, 2016. 69(7): p. 652-4.
76. Zhang Y, Wang F, Chen X, *et al.* Companion gene mutations and their clinical significance in AML with double mutant CEBPA. *Cancer Gene Ther*, 2019.